SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-24-000350
Filing Date
2024-04-04
Accepted
2024-04-04 16:39:37
Documents
2
Group Members
ORBIMED CAPITAL GP VII LLCORBIMED CAPITAL LLCORBIMED GENESIS GP LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 ss3223565_sc13da.htm SC 13D/A 115708
2 JOINT FILING AGREEMENT ss3223565_ex9901.htm EX-99.1 6306
  Complete submission text file 0000947871-24-000350.txt   123747
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Subject) CIK: 0001672619 (see all company filings)

IRS No.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91465 | Film No.: 24823629
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)